title: Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
abstract: We report the results of a phase I study of intravenously administered cisplatin, 5-fluorouracil and high-dose folinic acid. This trial was designed to exploit potential biochemical interactions between these three agents. The maximum tolerated doses were cisplatin, 75 mg/m2, day 1; 5-fluorouracil, 375 mg/m2, days 1-5 and leucovorin 500 mg/m2, days 1-5. The dose-limiting toxic effect of this regimen was myelosuppression. Mild non-hematologic toxic effects were also observed and included nausea, vomiting, stomatitis, and diarrhea. Phase II trial of this regimen are underway, however randomized studies will eventually be necessary to establish whether cisplatin contributes clinically significant activity to this regimen.
authors.affiliation: Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
authors.forename: J L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: R
authors.initials: R
authors.lastname: Amato
authors.forename: S
authors.initials: S
authors.lastname: Schmidt
authors.forename: M N
authors.initials: MN
authors.lastname: Raber
authors.forename: P
authors.initials: P
authors.lastname: Frost
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D012107:Research Design
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil